Scholarlink

Purpose <p>A hypoxic tumor microenvironment promotes cancer progression, with endothelin-A receptor (ET<sub>A</sub>R) signaling playing a key role in tumor neoangiogenesis and macrophage infiltration. We hypothesize that multispectral optoacoustic tomography (MSOT) using an ET<sub>A</sub>R-specific probe could provide improved insights into the hypoxic characteristics of the tumor microenvironment (TME), either alone or in combination with endogenous markers, and that alterations in ET<sub>A</sub>R expression may correlate with increased tumor oxygenation serving as an early indicator of response to anti-angiogenic or immune-modulating therapy.</p> Methods <p>A fluorescent ET<sub>A</sub>R probe was applied for in vivo MSOT evaluation of ET<sub>A</sub>R expression in hypoxic murine breast cancer. Optoacoustic signal intensity (SI) of deoxygenated and oxygenated hemoglobin served as additive intrinsic readouts. Furthermore, therapeutic interventions utilizing <i>Bevacizumab</i>, <i>Clodronate</i> and <i>Sorafenib</i> were evaluated with regard to effects on ET<sub>A</sub>R expression and hemoglobin oxygen saturation. Imaging results were validated ex vivo via immunohistochemistry.</p> Results <p>Exposure of 4T1 murine breast cancer cells to hypoxic conditions led to upregulation of ET<sub>A</sub>R in vitro. In vivo, tumor growth correlated with increased ET<sub>A</sub>R probe signal intensity in 4T1 tumors. All therapeutic interventions significantly reduced ET<sub>A</sub>R SI following treatment. Anti-angiogenic therapies also increased tumor oxygen saturation, indicating therapy-induced re-oxygenation.</p> Conclusion <p>ET<sub>A</sub>R expression in hypoxic tumor regions can be visualized non-invasively by MSOT using an exogenously administered targeted probe. Combining ET<sub>A</sub>R-targeted imaging with intrinsic hemoglobin readouts enables assessment of reoxygenation and immune cell modulation in response to therapy. Thus, ET<sub>A</sub>R has potential as an in vivo imaging biomarker for early therapy response in experimental breast cancer studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月13日

查看全文
  • Carsten Höltke,
  • Moushami Mallik,
  • Miriam Stölting,
  • Emily Hoffmann,
  • Christiane Geyer,
  • Raghu Erapaneedi,
  • Friedemann Kiefer,
  • Anne Helfen

摘要

Purpose

A hypoxic tumor microenvironment promotes cancer progression, with endothelin-A receptor (ETAR) signaling playing a key role in tumor neoangiogenesis and macrophage infiltration. We hypothesize that multispectral optoacoustic tomography (MSOT) using an ETAR-specific probe could provide improved insights into the hypoxic characteristics of the tumor microenvironment (TME), either alone or in combination with endogenous markers, and that alterations in ETAR expression may correlate with increased tumor oxygenation serving as an early indicator of response to anti-angiogenic or immune-modulating therapy.

Methods

A fluorescent ETAR probe was applied for in vivo MSOT evaluation of ETAR expression in hypoxic murine breast cancer. Optoacoustic signal intensity (SI) of deoxygenated and oxygenated hemoglobin served as additive intrinsic readouts. Furthermore, therapeutic interventions utilizing Bevacizumab, Clodronate and Sorafenib were evaluated with regard to effects on ETAR expression and hemoglobin oxygen saturation. Imaging results were validated ex vivo via immunohistochemistry.

Results

Exposure of 4T1 murine breast cancer cells to hypoxic conditions led to upregulation of ETAR in vitro. In vivo, tumor growth correlated with increased ETAR probe signal intensity in 4T1 tumors. All therapeutic interventions significantly reduced ETAR SI following treatment. Anti-angiogenic therapies also increased tumor oxygen saturation, indicating therapy-induced re-oxygenation.

Conclusion

ETAR expression in hypoxic tumor regions can be visualized non-invasively by MSOT using an exogenously administered targeted probe. Combining ETAR-targeted imaging with intrinsic hemoglobin readouts enables assessment of reoxygenation and immune cell modulation in response to therapy. Thus, ETAR has potential as an in vivo imaging biomarker for early therapy response in experimental breast cancer studies.